Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers

Abstract Objective: The aim of this study was to explore the clinical effects of intralesional administration of an epidermal growth factor (EGF) up to complete wound closure. Methods: Seventeen diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution were enrol...

Full description

Saved in:
Bibliographic Details
Published in:Growth factors (Chur, Switzerland) Switzerland), 2015-04, Vol.33 (2), p.128-132
Main Authors: Dumantepe, Mert, Fazliogullari, Osman, Seren, Mustafa, Uyar, Ibrahim, Basar, Fahrettin
Format: Article
Language:English
Subjects:
Amputation and epidermal growth factor
diabetic foot ulcers
wound healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective: The aim of this study was to explore the clinical effects of intralesional administration of an epidermal growth factor (EGF) up to complete wound closure. Methods: Seventeen diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution were enrolled in the study. Mean ulcer size was 15.5 +/− 7.5 cm2. Intralesional injections of 75 µg of Heberprot-P three times per week for 5-8 weeks were given up to complete wound healing. Results: Full granulation response was achieved in all patients in 32.4 +/− 6.6 days. Complete wound closure was obtained in 16 (94.1%) cases in 53.1 +/− 4.7 days. The most frequent adverse events were burning sensation, tremors, chills and pain at the site of administration. After 1-year follow-up, only one patient relapsed. Conclusions: Intralesional EGF administration up to complete closure can be safe, effective and suitable to improve healing of chronic diabetic foot ulcer (DFU).
ISSN:0897-7194
1029-2292
DOI:10.3109/08977194.2015.1031898